RAIN - Rain Oncology to Present At Oppenheimer 33rd Annual Healthcare Conference

NEWARK, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with its lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced that Avanish Vellanki, Chief Executive Officer of Rain, will be presenting a corporate overview at the Oppenheimer 33 ^rd Annual Healthcare Conference on Monday, March 13, 2023, at 11:20 a.m. ET, in a virtual format.

A live webcast of the presentation can be accessed here . A replay of the event will be available on the “ Events ” section of the Rain website after the conclusion of the event and will be archived on the Rain website at www.rainoncology.com .

About Rain Oncology Inc.
Rain Oncology Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, milademetan, is a small molecule, oral inhibitor of the MDM2-p53 complex that reactivates p53. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

Media Contact
Jordyn Temperato
LifeSci Communications
jtemperato@lifescicomms.com

Investor Contact
Dan Ferry
LifeSci Advisors
+1.617.430.7576
daniel@lifesciadvisors.com